

TEZSPIRE
(tezpelumab-ekko)**RATIONALE FOR INCLUSION IN PA PROGRAM****Background**

Tezspire (tezpelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2I that binds to human TSLP and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in the asthma inflammatory cascade. Blocking TSLP reduces biomarkers and cytokines associated with inflammation. Airway inflammation is an important component in the pathogenesis of asthma (1).

Regulatory Status

FDA-approved indication: Tezspire is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2I), indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma (1).

Limitations of Use: (1)

- Not for relief of acute bronchospasm or status asthmaticus.

Tezspire contains warnings regarding the following: hypersensitivity reactions; acute asthma symptoms or deteriorating disease; risk associated with abrupt reduction of corticosteroid dosage; parasitic (helminth) infection; and live attenuated vaccines (1).

FEP adherence is defined as $\geq 50\%$ utilization within the last 180 days.

The safety and effectiveness of Tezspire in pediatric patients less than 12 years of age have not been established (1).

Summary

Tezspire (tezpelumab-ekko) is a TSLP blocker and human monoclonal antibody that is used for the add-on maintenance treatment of patients 12 years and older with severe asthma. Tezspire is not used for the relief of acute bronchospasm or status asthmaticus. It is also recommended to avoid the use of live attenuated vaccines with Tezspire. The safety and effectiveness of Tezspire in pediatric patients less than 12 years of age have not been established (1).



**BlueCross
BlueShield**

Federal Employee Program.

**TEZSPIRE
(tezepelumab-ekko)**

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Tezspire while maintaining optimal therapeutic outcomes.

References

1. Tezspire [package insert]. Thousand Oaks, CA: AstraZeneca AB, Inc.; February 2023.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from www.ginasthma.org.